News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Brian Ellman, MBA

Articles by Brian Ellman, MBA

Evaluating Dose Ratio of Subcutaneous to Intravenous Immunoglobulin Therapy Among Patients With Primary Immunodeficiency Disease Switching to 20% Subcutaneous Immunoglobulin Therapy

ByGirishanthy Krishnarajah, MPH, MBA/MS, PhD,Jee-Yeon K. Lehmann, PhD,Brian Ellman, MBA,Rachel H. Bhak, MS,Maral DerSarkissian, PhD,Deane Leader, Jr, PhD, MBA,Ann L. Bullinger, PharmD,Mei

October 21st 2016

Latest Updated Articles

Evaluating Dose Ratio of Subcutaneous to Intravenous Immunoglobulin Therapy Among Patients With Primary Immunodeficiency Disease Switching to 20% Subcutaneous Immunoglobulin Therapy
Published: October 21st 2016 | Updated:

Trending on AJMC

Proactive MG Management Hinges on Better Coverage and Guidelines

Misinformation and Knowledge Gaps Undermine Vaccine Protection: Kristina Crothers, MD

Provider Shortages, Coverage, Cost Are Top Barriers to Care: CHEST 2025 Experts

FDA Expands Sotatercept Indication for PAH

With New OUD Diagnoses on the Rise, More Comprehensive Screenings Needed

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

© 2025 MJH Life Sciences^®

All rights reserved.